Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 3551-3557, May 15, 2008. doi: 10.1158/0008-5472.CAN-07-5835
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Loeb, L. A.
Right arrow Articles by Bodmer, I. W.
PubMed
Right arrow Articles by Loeb, L. A.
Right arrow Articles by Bodmer, I. W.
Related Collections
Right arrow Cellular Pathobiology
Right arrow Cellular Pathobiology: DNA Damage and Stress Responses
Right arrow Point-Counterpoint

Cancers Exhibit a Mutator Phenotype: Clinical Implications

Lawrence A. Loeb1, Jason H. Bielas1 and Robert A. Beckman2,3

1 Department of Pathology, University of Washington School of Medicine, Seattle, Washington; 2 Oncology Clinical Research, Merck Research Laboratories, North Wales, Pennsylvania; and 3 Simons Center for Systems Biology, Institute for Advanced Study, Princeton, New Jersey

Requests for reprints: Lawrence A. Loeb, Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195-7470. Phone: 206-543-6015; Fax: 206-543-3967; E-mail: larryloeb{at}earthlink.net.

Abstract

Malignancies are characterized by mutations. We have hypothesized that the thousands of mutations in most human cancers do not result from the low mutation rates exhibited by normal human cells. Instead, cancer cells express a mutator phenotype (i.e., the mutation rate in the cancer cells is much greater than that in normal cells). We consider the following points: (a) Mutations in genes that govern genetic stability could be the cause of a mutator phenotype exhibited by human cancers. (b) A mutator phenotype increases the efficiency of acquiring mutations including those associated with cancer. (c) Recent experimental evidence indicates that human tumors contain a vast array of both clonal mutations and nonexpanded (random) mutations. (d) The presence of nonexpanded mutations in tumors has fundamental clinical implications for cancer risk assessment, grading, and prognosis including the rapid emergence of resistance to chemotherapeutic agents. Lastly, (e) if a mutator phenotype drives carcinogenesis, drugs that target mutator pathways might prevent cancer by delay. [Cancer Res 2008;68(10):3551–7]


Reviews

Cancers Exhibit a Mutator Phenotype: Clinical Implications

Lawrence A. Loeb1, Jason H. Bielas1 and Robert A. Beckman2,3

1 Department of Pathology, University of Washington School of Medicine, Seattle, Washington; 2 Oncology Clinical Research, Merck Research Laboratories, North Wales, Pennsylvania; and 3 Simons Center for Systems Biology, Institute for Advanced Study, Princeton, New Jersey

Requests for reprints: Lawrence A. Loeb, Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195-7470. Phone: 206-543-6015; Fax: 206-543-3967; E-mail: larryloeb{at}earthlink.net.

Abstract

Malignancies are characterized by mutations. We have hypothesized that the thousands of mutations in most human cancers do not result from the low mutation rates exhibited by normal human cells. Instead, cancer cells express a mutator phenotype (i.e., the mutation rate in the cancer cells is much greater than that in normal cells). We consider the following points: (a) Mutations in genes that govern genetic stability could be the cause of a mutator phenotype exhibited by human cancers. (b) A mutator phenotype increases the efficiency of acquiring mutations including those associated with cancer. (c) Recent experimental evidence indicates that human tumors contain a vast array of both clonal mutations and nonexpanded (random) mutations. (d) The presence of nonexpanded mutations in tumors has fundamental clinical implications for cancer risk assessment, grading, and prognosis including the rapid emergence of resistance to chemotherapeutic agents. Lastly, (e) if a mutator phenotype drives carcinogenesis, drugs that target mutator pathways might prevent cancer by delay. [Cancer Res 2008;68(10):3551–7]


 
I. Walter Bodmer

Cancer and Immunogenetics Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom




This article has been cited by other articles:


Home page
CRO ContentHome page
G. C. Prendergast
From Sturm und Drang to Zebrafish
Cancer Reviews Online Content, June 1, 2008; 2008(6): 11 - 11.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.